Stephen Liu
MD
Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics
Georgetown Lombardi Comprehensive Cancer Center
May 03, 2021
Episode
64
Soundcloud
Share
This episode of Lung Cancer Considered covers recent promising results with new targeted agents for NSCLC harboring a KRAS G12C mutation. Thoracic oncologists have long thought this condition was undruggable, but results presented at WCLC 2020 from the CodeBreak 100 trial provide hope that new therapies will be more readily available.
Guest
